Influence of Pioglitazone for Renal Transplant Function in Diabetics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00507494|
Recruitment Status : Completed
First Posted : July 26, 2007
Last Update Posted : October 28, 2011
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Kidney Transplantation Proteinuria||Drug: pioglitazone||Phase 3|
About 30 % of kidney transplant recipients will develop diabetes mellitus. This condition is a risk factor for graft dysfunction, graft loss and increased mortality of patients. Inflammatory reactions within the graft and proteinuria are considered as pathogenetic mechanisms.
Recent studies indicated that pioglitazone might have beneficial effects on the urinary protein excretion of type 2 diabetic patients with diabetic nephropathy and was able to reduce systemic inflammation.
This lead to the hypothesis that pioglitazone could improve proteinuria of kidney transplant patients with diabetes.
Comparison: Effects of pioglitazone vs. placebo on proteinuria and renal function of kidney transplant recipients in a cross over study.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Official Title:||Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2009|
- proteinuria [ Time Frame: 12 weeks ]
- efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507494
|Nephrology, Department of Medicine, university hospital Dresden|
|Dresden, Germany, 01307|
|Principal Investigator:||Peter Gross, MD||Nephrology, Department of Medicine, University hospital Dresden|